CINCINNATI, March 17, 2017 /PRNewswire/ -- Cincinnati, Ohio-based Malibu Group, a boutique investment banking and strategic advisory firm focused on selling Midwest private companies, has added a new member to its ownership group and rebranded itself as ArkMalibu. The announcement comes as the company confirms completion of a deal between Camargo Pharmaceutical Services, a leader in its industry, and a private non-institutional investment firm. This partnership will enable Camargo to take a long-term, disciplined approach to expand and develop new capabilities, drive growth in the accelerating 505(b)(2) market, and facilitate an increased global presence in drug development consulting. The investment firm was attracted to Camargo's position as the market leader in this rapidly growing drug development consulting space, the Company's growth prospects, and the alignment with the management team. ArkMalibu provided strategic financial advice under the leadership of the firm's new partner, Rene Robichaud, who will continue to serve as chairman of ArkMalibu's board of advisors. The firm's founder, Peter Kubasek, makes up the other half of the new ownership group and will continue as chief executive officer of ArkMalibu.
Following a busy year advising on a variety of M&A transactions, ArkMalibu closed the Camargo Pharmaceutical Services transaction to kick off 2017. The match was made after a thorough review of the company, its industry and more than 100 potential investors. ArkMalibu worked to identify a partner who aligned with the client's corporate culture, growth strategy and overall goals. "ArkMalibu's efforts have resulted in Camargo being a better company. They led us to recognize and leverage our cultural values and we look forward to rapidly growing our company in the coming years," said Ken Phelps, Chief Executive Officer of Camargo Pharmaceutical Services.
"ArkMalibu's efforts during due diligence and papering the deal were instrumental in keeping it moving all the way through close," added Ruth Stevens, Chief Science Officer of Camargo Pharmaceutical Services.
"ArkMalibu's focus has always been on Midwestern, private companies, many of which are family owned," said Robichaud. "Regardless of company size, we're looking out for the seller. Our business model focuses on sell-side transactions, which is how we stay free of conflicts of interest. In other words, we do not find ourselves negotiating against potential clients. For most of our clients, this is the biggest deal they're going to do in their lives. They're selling their business, and they have one chance to get it right. We take that responsibility very seriously."
Two examples of these clients are featured in deals that ArkMalibu helped negotiate in 2016. The first included leading the sale process for the multi-generational, family-owned school supply business, John R. Green Company, which sold to Kurtz Bros., a strategic buyer. The other was with Connext, a leading lender in industrial equipment finance, who partnered with Engs Commercial Finance Company. The combination of Engs' nationally recognized transportation finance vertical and Connext's industrial equipment vertical will generate $500 million in annual lease and loan originations and expand Engs' footing as one of the largest independent commercial finance companies in the U.S.
For ArkMalibu, the firm's own growth plan for 2017 is aggressive as the new ownership group builds on its vision to help more companies find their right partner through mergers and acquisitions. "As a firm, we're able to help people execute complex transactions during one of the most significant times of their lives. Sometimes it's not just about finding the highest bidder, it's about protecting a legacy they've built for years and in many cases over generations. It's also about finding a partner who will honor that legacy and build future success around it," said Kubasek.
About ArkMalibu (formerly The Malibu Group)
Based in Cincinnati, Ohio, ArkMalibu is an investment banking boutique serving privately-held businesses. Founded in 1990 by Peter Kubasek, the firm has established a strong reputation as a creative and trusted M&A advisor with an ability to deliver value well above market expectations for mergers and acquisitions. In 2016, Rene Robichaud formalized a partnership with Peter Kubasek to establish ArkMalibu. The 'Ark' in ArkMalibu represents 'the Associates of Robichaud and Kubasek'. The firm continues to add talent to its team and to focus on leading sell-side transactions while providing advisory services for clients. It is one of the only investment banks to win the Torch Award from the Better Business Bureau (2006) and was the 2010 recipient of the Association of Corporate Growth's (ACG) Deal Maker of the Year and is a Finalist for the 2016 ACG Deal Maker of the Year award. To learn more about ArkMalibu, please visit http://arkmalibu.com.
About Camargo Pharmaceutical Services
Camargo has established an unrivaled track record of drug development utilizing the 505(b)(2) pathway and the global equivalent processes. Experts at Camargo have participated in more than 1,100 Agency meetings, resulting in over 200 drug approvals. The Company has more than 30 PhDs with expertise in drug development, including comprehensive in-house specializations of pharmacokinetics; toxicology; and Chemistry, Manufacturing, and Controls (CMC), with offices in Durham, North Carolina, and Cincinnati, Ohio. To learn more about Camargo Pharmaceutical Services, please visit http://camargopharma.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arkmalibu-advises-camargo-pharmaceutical-services-in-recent-transaction-with-private-investment-firm-300425423.html